Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 49
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 716-729
Open Access | Times Cited: 29
Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions
Xiaoyu Gang, Jinshan Yan, Xin Li, et al.
Cancer Letters (2024) Vol. 604, pp. 217241-217241
Open Access | Times Cited: 12
Cancer vaccines: current status and future directions
Yi Zhou, Yuquan Wei, Xiaohe Tian, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
The potential applications of peptide-loading complex in cancer treatment
Zhidu Song, Ying Tao, Jiaxin You
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Therapeutic vaccines for advanced non-small cell lung cancer
Marcela Cortés-Jofré, Mikel Rueda-Etxebarria, Émeline Orillard, et al.
Cochrane library (2024) Vol. 2024, Iss. 3
Closed Access | Times Cited: 8
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Nikolaj Frost, Martin Reck
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
The progress of tumor vaccines clinical trials in non-small cell lung cancer
Xiaomu Wang, Yunping Niu, 芳久 渡辺
Clinical & Translational Oncology (2024) Vol. 27, Iss. 3, pp. 1062-1074
Open Access | Times Cited: 5
Harnessing Bacterial Membrane Components for Tumor Vaccines: Strategies and Perspectives
Zhenxin Bai, Xuanyu Wang, Tianming Liang, et al.
Advanced Healthcare Materials (2024)
Closed Access | Times Cited: 4
Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression
Achilleas Mitrakas, Christos Kakouratos, Ioannis Lamprou, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 853-853
Open Access
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors
S.V. Liu, R. Dziadziuszko, Santiago Viteri, et al.
Lung Cancer (2025), pp. 108516-108516
Closed Access
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Annapaola Mariniello, Maxime Borgeaud, Marc Weiner, et al.
BioDrugs (2025)
Open Access
Preparation and Evaluation of Meclinertant-loaded PLGA/Chitosan Nanoparticles as a Potential Treatment for Non-Small Cell Lung Cancer Using A549 Cells.
Parth Patel, Nicole Oyinade Shoyele, Sunday Shoyele
Journal of Drug Delivery Science and Technology (2025), pp. 106831-106831
Open Access
Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response
Courtney H. Coschi, Rosalyn A. Juergens
Current Oncology (2023) Vol. 31, Iss. 1, pp. 1-23
Open Access | Times Cited: 7
Vaccine-based therapeutic interventions in lung cancer management: A recent perspective
Dhruv Gupta, Daksh Sanjay Gupta, Nosheen Kamruddin Abjani, et al.
Medical Oncology (2024) Vol. 41, Iss. 11
Closed Access | Times Cited: 2
Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor
Mengjiao Wang, Quan Wan, Chenglv Wang, et al.
Molecular and Cellular Biochemistry (2024)
Closed Access | Times Cited: 1
Novel vaccines against lung cancer
Sofia Baka, George Iraklis, Evanthia Papadopoulou
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan
Ticiana Leal, Anandaroop Dasgupta, Dominick Latrémouille-Viau, et al.
JCO Global Oncology (2024), Iss. 10
Open Access | Times Cited: 1
Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
Jyoti Malhotra, Amy Huang, Arya Amini, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3603-3603
Open Access | Times Cited: 1
Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer
Rui Tang, Haitao Wang, Mingxi Tang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Shrinking sample sizes in lung cancer trials: Various explanations, open questions
Timothée Olivier, Alfredo Addeo
European Journal of Cancer (2024) Vol. 199, pp. 113527-113527
Closed Access
Preliminary response to Tislelizumab plus chemotherapy drugs in patient with periampullary carcinoma: a report of one case and a literature review
Chuanyun Tang, Yijie Kong, Lifan Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
Rayan Kabirian, Olivier Trédan, Frederik Marmé, et al.
Future Oncology (2024) Vol. 20, Iss. 35, pp. 2699-2708
Closed Access
Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
Georgia Gomatou, Andriani Charpidou, Peifeng Li, et al.
Clinical & Translational Oncology (2024)
Closed Access
Identification and evaluation of tumor pyroptosis-associated antigens for design a vaccine candidate against lung cancer
Truc Ly Nguyen, Heebal Kim
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top